Table 2.

Overview of clinical trials for investigated agents targeting Wnt signaling pathway.

Agent	Target Component	Trial Phase and Identifier	Condition or Disease	Collaborator and Sponsor
WNT974	Porcupine inhibitor	Phase 1 NCT01351103	Pancreatic cancer, BRAF mutant colorectal cancer, melanoma, triple-negative breast cancer, head and neck squamous cell cancer, cervical squamous cell cancer, esophageal squamous cell cancer, and lung squamous cell cancer	Novartis Pharmaceuticals
WNT974 (in combination with LGX818 and cetuximab)	Porcupine inhibitor	Phase 1 and 2 NCT02278133	Metastatic colorectal cancer with BRAFV600-mutant mCRC with RNF43 mutations or RSPO fusions.	Array BioPharma
Foxy-5	Wnt-5A mimetic	Phase 1 and 2 NCT02020291 NCT02655952 NCT03883802	Metastatic breast cancer, colorectal cancer, prostate cancer, colon cancer	WntResearch AB, SMS-Oncology BV, SAGA Diagnostics AB, Unilabs A/S, BioVica AB, Catalan Institute of Oncology
ETC-159	Porcupine inhibitor	Phase 1 NCT02521844	Solid tumors	EDDC (Experimental Drug Development Centre), A*STAR Research Entities, PPD
Ipafricept (OMP54F28)	Decoy Fzd8-receptor	Phase 1 NCT01608867	Solid tumors	Bayer; OncoMed Pharmaceuticals, Inc.
Vantictumab (OMP-18R5)	Anti-FZD antibody	Phase 1 NCT01345201 NCT02005315 NCT01957007 NCT01973309	Solid tumors, pancreatic cancer stage IV, pancreatic cancer, non-small-cell lung cancer, metastatic breast cancer	OncoMed Pharmaceuticals, Inc.
2X-121	Tankyrase inhibitors	Phase 2 NCT03562832 NCT03878849	Metastatic breast cancer, advanced ovarian cancer	Oncology Venture, Smerud Medical Research International AS, Danish Breast Cancer Cooperative Group, Alcedis GmbH, Amarex Clinical Research
PRI-724	Inhibitor of TCF/β-catenin transcription complex	Phase 1 and 2 NCT01606579	Advanced myeloid malignancies	inVentiv Health Clinical; Prism Pharma Co., Ltd.
PRI-724	Inhibitor of TCF/β-catenin transcription complex	Phase 1 NCT01302405	Advanced solid tumors	inVentiv Health Clinical; Prism Pharma Co., Ltd.